Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%

Dr. Reddy’s Laboratories Ltd RDY reported Tuesday a second-quarter 2025 net income of $160 million, down from $177 million a year ago.

Revenue increased from $821 million to $957 million — almost a 16.6% jump.

The strong revenue growth during the quarter was primarily driven by growth in global generics revenues. The sequential growth was led by global generics revenues in Emerging Markets, India, Europe and Pharmaceutical Services and Active Ingredients (PSAI).

EBITDA for the quarter rose from $260 million to $272 million.

“We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell and related brands,” said co-chair GV Prasad.

Global generics revenues during the second quarter reached 71.6 billion rupees, showing a 17% year-over-year growth, driven by improved sales volumes and new product launches.

North American sales increased 17% (a sequential decline of 3%) to 37.3 billion rupees. YoY growth was largely due to increased sales volumes, partly offset by price erosion. The sequential decline was due to a decrease in sales volumes.

Gross Margin at 59.6% (GG: 63.1 %, PSAI: 30.0%), a YoY increase of 92 basis points (bps) and a QoQ decline of 81 bps. The YoY increase was due to an improvement in product mix and overhead leverage, partly offset by price erosion. On a sequential basis, the decline was primarily due to changes in the mix.

Price Action: Dr. Reddy’s Laboratories is up 4.81% at $15.51 during the premarket session at last check Tuesday.

Read Next:

• Short Squeeze – GlobalFoundries Stock Soars On Q3 Earnings Beat, Strong Q4 Outlook